Short term administration of gonadotropin-releasing hormone analog to a patient with a testosterone-secreting ovarian tumor.

A GnRH superagonist, buserelin, was administered for 16 days to a postmenopausal woman with a testosterone-secreting ovarian tumor. Serum gonadotropin levels decreased by more than 70%, and serum testosterone fell by more than 50%. This short term study demonstrates that in these uncommon tumors androgen secretion is gonadotropin sensitive, and suggests that GnRH analogs may have therapeutic value in such patients.

[1]  R. Santen,et al.  Long term effects of administration of a gonadotropin-releasing hormone superagonist analog in men with prostatic carcinoma. , 1984, The Journal of clinical endocrinology and metabolism.

[2]  W. Crowley,et al.  Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. Effects on somatic growth and skeletal maturation. , 1983, The New England journal of medicine.

[3]  Y. Moon,et al.  Adrenal and sex steroid hormone production by a virilizing adrenal adenoma and its diagnosis with computerized tomography. , 1983, American journal of obstetrics and gynecology.

[4]  J. Klijn,et al.  TREATMENT WITH A LUTEINISING-HORMONE-RELEASING-HORMONE ANALOGUE (BUSERELIN) IN PREMENOPAUSAL PATIENTS WITH METASTATIC BREAST CANCER , 1982, The Lancet.

[5]  D Ackman,et al.  Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists. , 1982, Proceedings of the National Academy of Sciences of the United States of America.

[6]  S. Lamberts,et al.  Testosterone secretion by cultured arrhenoblastoma cells: suppression by a luteinizing hormone-releasing hormone agonist. , 1982, The Journal of clinical endocrinology and metabolism.

[7]  W. Crowley,et al.  Short-term treatment of idiopathic precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. A preliminary report. , 1981, The New England journal of medicine.

[8]  B. J. Davidson,et al.  LONG-STANDING VIRILISM IN A WOMAN WITH HYPERPLASIA AND NEOPLASIA OF OVARIAN LIPIDIC CELLS , 1981, Obstetrics and gynecology.

[9]  R. Sabet,et al.  Virilizing adrenal adenoma with studies on the steroid content of the adrenal venous effluent and a review of the literature. , 1981, Endocrine reviews.

[10]  J. Gonzalez‐Vitale,et al.  Steroid section patterns of a hilus cell tumor of the ovary. , 1981, Obstetrics and gynecology.

[11]  G. Sutton,et al.  Steroid secretion and testosterone binding in a woman with an ovarian hilus cell tumor and thyrotoxicosis. , 1981, American Journal of Obstetrics and Gynecology.

[12]  V. James,et al.  A simple non-chromatographic radioimmunoassay for plasma androstenedione. , 1979, Journal of steroid biochemistry.

[13]  H. Taubert,et al.  The effect of D-ser (TBU)6-LH-RH-EA10 upon gonadotropin release in normally cyclic women. , 1977, The Journal of clinical endocrinology and metabolism.

[14]  H. Judd,et al.  A testosterone-producing adrenal cortical adenoma in an elderly woman. , 1976, The Journal of clinical endocrinology and metabolism.

[15]  P. V. Bertrand,et al.  A radioimmunoassay for the estimation of serum dehydroepiandrosterone sulphate in normal and pathological sera. , 1975, Clinica chimica acta; international journal of clinical chemistry.

[16]  K. Benirschke,et al.  Preoperative localization of a testosterone-secreting ovarian tumor by retrograde venous catheterization and selective sampling. , 1974, American journal of obstetrics and gynecology.

[17]  J. Tucci,et al.  Endocrine studies in an arrhenoblastoma responsive to dexamethasone, ACTH and human chorionic gonadotropin. , 1973, The American journal of medicine.

[18]  E. Werk,et al.  Testosterone-secreting adrenal adenoma under gonadotropin control. , 1973, The New England journal of medicine.

[19]  R. Vihko,et al.  Plasma steroids in two subjects with ovarian androgen-producing tumors arrhenoblastoma and gynandroblastoma. , 1972, The Journal of clinical endocrinology and metabolism.

[20]  T. Sato,et al.  A clinical and metabolic study of masculinizing arrhenoblastoma. , 1969, American journal of obstetrics and gynecology.

[21]  M. Batrinos,et al.  Individual 17-ketosteroid excretion in a case of arrhenoblastoma and its response to corticotrophin and human chorionic gonadotrophin stimulation and to dexamethasone inhibition. , 1966, The Journal of clinical endocrinology and metabolism.